文献速递显微修复重建创面修复

局部免疫抑制用于血管化复合组织移植:非人灵长类模型中FK506-TyroSpheres的应用

Local Immunosuppression for Vascularized Composite Allografts: Application of Topical FK506-TyroSpheres in a Nonhuman Primate Model.
PubMed 文献 · J Burn Care Res · 2020-01-01

本研究在MHC错配的食蟹猴前臂筋膜皮瓣VCA模型中,比较局部涂抹FK506-TyroSpheres凝胶敷料与标准杆菌肽软膏的效果。结果显示,即使使用FK506-TyroSpheres,当全身FK506水平低于10 ng/ml时仍出现VCA排斥临床特征,未能延长移植物存活,但TyroSphere技术避免了不必要的全身FK506吸收。

要点

  • 局部FK506-TyroSpheres未能延长非人灵长类VCA存活。
  • 全身FK506低于10 ng/ml时仍发生VCA排斥。
  • TyroSphere技术可避免全身FK506吸收。

核心结论

  • 局部应用FK506-TyroSpheres在全身FK506低于10 ng/ml时未能防止VCA排斥或延长移植物存活。
  • TyroSphere技术避免了不必要的全身FK506吸收。

研究设计与样本

  • 研究采用6只MHC错配的食蟹猴作为前臂桡侧筋膜皮瓣VCA的互相供受体。
  • 对照组(n=2)使用标准杆菌肽软膏,实验组(n=4)使用FK506-TyroSpheres凝胶敷料,隔日涂抹,随后逐渐减量全身FK506。

主要发现

  • 尽管应用FK506-TyroSpheres,当全身FK506水平降至10 ng/ml以下时,VCA仍出现排斥的临床特征。
  • 未实现VCA存活的延长。
  • TyroSphere技术避免了不必要的全身FK506吸收。

临床怎么用

  • 当前FK506-TyroSpheres局部给药方案尚不足以在降低全身免疫抑制时维持VCA存活。
  • 需进一步优化局部药物递送方案以达到并维持FK506的治疗性释放。

局限性

  • 样本量小(对照组n=2,实验组n=4)。
  • 仅使用一种非人灵长类VCA模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplantation of vascularized composite allografts (VCAs) provides a means of restoring complex anatomical and functional units following burns and other disfigurement otherwise not amenable to conventional autologous reconstructive surgery. While short- to intermediate-term VCA survival is largely dependent on patient compliance with medication, the myriad of side effects resulting from lifelong systemic immunosuppression continue to pose a significant challenge. Topical immunosuppression is therefore a logical and attractive alternative for VCA. Current formulations are limited though, by poor skin penetration but this may be mitigated by conjugation of immunosuppressive drugs to TyroSpheres for enhanced delivery. Therefore, we investigated the topical application of FK506-TyroSpheres (in the form of a gel dressing) in a clinically relevant nonhuman primate VCA model to determine if allograft survival could be prolonged at reduced levels of maintenance systemic immunosuppression. Six Major Histocompatibility Complex (MHC)-mismatched cynomolgus macaques (Macaca fascicularis) served as reciprocal donors and recipients of radial forearm fasciocutaneous flaps. Standard Bacitracin ointment and FK506-TyroSpheres were applied every other day to the VCAs of animals in groups 1 (controls, n = 2) and 2 (experimental, n = 4), respectively, before gradual taper of systemic FK506. Clinical features of VCA rejection still developed when systemic FK506 fell below 10 ng/ml despite application of FK506-TyroSpheres and prolonged VCA survival was not achieved. However, unwanted systemic FK506 absorption was avoided with TyroSphere technology. Further refinement to optimize local drug delivery profiles to achieve and maintain therapeutic delivery of FK506 with TyroSpheres is underway, leveraging significant experience in controlled drug delivery to mitigate acute rejection of VCAs.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Gama AR, Ng ZY, Shanmugarajah K, et al. Local Immunosuppression for Vascularized Composite Allografts: Application of Topical FK506-TyroSpheres in a Nonhuman Primate Model. J Burn Care Res. 2020. PMID: 32352521. doi:10.1093/jbcr/iraa062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。